Arch Grants
  • Origin: Missouri
  • Grant awarded in: 2017

Involved Industries:


Contact Information

Facebook

Twitter

LinkedIn


Support Organizations:


What is VaxNewMo?


VaxNewMo is dedicated to developing more affordable pneumococcal conjugate vaccines that provide broader protection against more strains of bacteria that cause pneumococcal pneumonia. To do this, we utilize our patented bioconjugation technology, which bypasses the dependency on the synthetic chemistry techniques previously required to manufacture conjugate vaccines. In essence, we have engineered the lab safe bacterium, E. coli, to manufacture pneumococcal conjugate vaccines faster, more reliable, and less expensive than traditional pharmaceutical companies can.


Company Leadership


Christian Harding

Christian Harding is Co-Founder and Chief Scientific Officer for VaxNewMo.


Mario Feldman


Christine Szymanski


Jason Ding



Similar Startups

Other companies you might be interested in: